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vancomycin and daptomycin. Second line intravenous daptomycin was assumed 
to be administered via an outpatient parenteral treatment service. ConClusions: 
Findings suggest that use of first-line linezolid in the management of MRSA-cSSTIs 
could result in savings for the third-party payer in Greece accompanied by enhanced 
quality of life results.
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MatheMatIcal Models of hePatItIs B VaccINatIoN aNd screeNINg 
PrograMMes IN the UNIted KINgdoM: a systeMatIc reVIew
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objeCtives: The United Kingdom (UK) has a targeted hepatitis B (HBV) vaccination 
programme for at-risk patient groups; however such a programme can be challeng-
ing to implement. The World Health Organisation (WHO) recommends universal 
HBV vaccination and this approach has been adopted by most developed countries. 
A systematic review was conducted to identify UK-based mathematical models for 
HBV to determine whether current evidence supports the use of a universal vaccina-
tion programme versus a targeted approach. Methods: Embase, Medline, Econlit 
and The Cochrane Library were searched for studies reporting HBV mathematical 
models (economic or epidemiological) in the UK population. Hand searching of 
Health Protection Agency and National Institute for Health and Clinical Excellence 
guidance documents was also performed. Economic models (cost-effectiveness, 
cost-utility, cost-benefit, cost-consequence) were included if they assessed HBV 
vaccination or screening programmes. Epidemiological studies were included if they 
modelled HBV immunity and infection rates. Data were independently extracted 
and summarised into evidence tables by two reviewers and quality appraisal of 
included studies was performed. Results: Electronic database searches identified 
a total of 649 citations resulting in 11 relevant publications. Hand searching yielded 
an additional two publications; a total of 13 included publications representing 
seven economic evaluations and six epidemiological modelling studies. Overall, 
there was considerable variation in model methodologies including methods of 
discounting used, static versus dynamic approaches and sources of model inputs. 
Only one epidemiological modelling study considered HBV transmission patterns 
across the UK. ConClusions: Current HBV vaccination policy in the UK is depend-
ent on the demonstration of cost-effectiveness. However, this review highlights 
some of the limitations inherent in the models which have been used to support 
policy decisions. Alternative modelling approaches, as well as new data on key 
inputs, are desirable if the full value of a universal HBV vaccination programme in 
the UK is to be assessed.
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rUssIa: aN ecoNoMIc eValUatIoN
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objeCtives: Today vaccination for children from 0 to 20 months in the Russian 
Federation is carried mainly by DPT and monovalent vaccines. As a result, a child 
of this age receives 12 injections. Vaccination against Hib infection so far is only 
available for children at risk (approx. 20%). Introdution of DTaP-IPV-Hib combined 
vaccine could reduce the number of injections received by the child and increase 
the coverage against Hib infection from 20% to 97%. The objective of the present 
study is to assess the economic evaluation of DTaP-IPV-Hib vaccine introduction 
into immunization schedule and select the most cost-effective vaccination scheme 
against Hib infection. Methods: A cost-effectiveness analysis of the DTaP-IPV-Hib 
vaccine is performed on suggested Markov model. The four vaccination schemes are 
intercompared : the current immunization program (Scheme0), a 3+1 immuniza-
tion DTaP-IPV-Hib vaccine (Scheme P), a mixed DTwP /DTaP-IPV-Hib immunization 
(Scheme mix) and a potential scenario - the current scheme, but with expanded 
(97%) Hib coverage - Scheme 1. The cohort of infants born in 2011 year is followed 
over their lifetime. Direct and indirect medical costs are measured from the perspec-
tive of the public payer. Outcomes are measured in life years gained (LYG).Exchange 
rate is 1€ = 41 rub. Results: According to the model, total costs of immunization 
Scheme are: 0 – 4216723519 rub. (102 846 915€ ), Scheme 1 –4924823829 rub.(120 117 
654€ ), Scheme P -6035132925rub.(147 198 364€ ), Scheme mix - 4 921 824 835 rub 
(120 044 508€ ). The values of cost/LYG are estimated at 4243 198 rub .(103493€ ) for 
Scheme 0, 1 224 270rub.(29860€ )for Scheme 1, 1500 283 rub. (36592€ ) for Scheme P, 
1223 525rub.(29842€ )– for Scheme mix. ConClusions: The introduction of DTaP-
IPV-Hib combined vaccine would bring improvement into the Russian immunization 
program through a Scheme mix.
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objeCtives: To evaluate the impact of different discounting approaches on economic 
evaluation using an example of Hepatitis B model. Currently, constant discounting 
rates of 3.5% are applied for costs and outcomes in the UK. This study applied different 
approaches such as empirical, stepwise and time-shifted discounting in parallel to 
the constant discounting to identify their respective impact on the cost-effectiveness 
results with respect to the NICE threshold. Methods: To compare costs and out-
comes of a vaccination policy, a Markov model was built for the UK population birth 
cohort. Patients entered after contracting Hepatitis B and were followed until 80 years 
old. The health states included chronic carrier phase, immune, compensated and 
decompensated cirrhosis, hepatocellular carcinoma and death. The different dis-
counting approaches were applied to the costs and health outcomes. The Incremental 
Cost-Effectiveness Ratios (ICERs) thus obtained were compared. Results: The ICER 
obtained was higher than the NICE threshold of £20,000 to £30,000 per QALY gained 
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objeCtives: Approximately 1.1 million people in the U.S. are living with HIV, with 
50,000 new infections per year. The FDA approved Stribild™, a once-daily HIV medi-
cation, in September of 2012. The primary objective of this study was to assess 
the cost and disease-related outcomes of Stribild versus guideline-recommended 
treatment options for HIV patients in a specialty retail pharmacy. A secondary objec-
tive was to assess compliance via Medication Possession Ratios (MPRs). Methods: 
HIV patients who were prescribed one of five antiretroviral regimens in the period 
from January 1, 2010 to June 21, 2013 and who obtained their medications through 
Schnucks Specialty Pharmacy were selected via a retrospective chart review. By 
measuring the direct cost of the medications to the pharmacy and the disease-
related outcomes, change in CD4 count and viral load suppression, the cost-effec-
tiveness of Stribild versus its comparators was assessed. Results: A total of 92 
patients were included in this study: 50 Stribild patients and 42 patients on alternate 
regimens: 15 Atripla®; 6 Isentress®; 10 Prezista®; and 11 Reyataz®. Incremental Cost-
Effectiveness Ratios (ICERs) were conducted between Stribild and the comparators 
for change in mean CD4 count and percent viral load suppression (< 20 copies/ml) 
achieved. In terms of CD4 count, Stribild was most cost-effective when compared 
to Prezista and least cost-effective when compared to Isentress. Analyses of viral 
load suppression indicated that Stribild is more cost-effective than Prezista and 
Reyataz but less cost-effective than Atripla or Isentress. Mean MPR was greater 
than 95% for Stribild and three of its comparators (not including Atripla); however, 
78 percent of Stribild patients achieved MPR ≥ 95% which demonstrates higher 
compliance than all comparators except the Isentress patients. ConClusions: 
The once-daily regimen Stribild appears effective at treating the HIV virus while 
maintaining compliance for most of its patients; its high cost remains a concern 
for formulary decision makers.
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cost-effectIVeNess of aNtIMIcroBIals as treatMeNt for PatIeNts 
wIth coMPlIcated sKIN aNd soft tIssUes INfectIoNs: a coMParIsoN 
BetweeN ceftarolINe, lINezolId aNd VaNcoMycIN IN the rUssIaN 
health care
Kulikov A., Komarov I.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To estimate the cost-effectiveness of antimicrobials (ceftaroline, 
linezolid and vancomycin) as treatment for patients with complicated skin and 
soft tissues infections. Methods: A literature-based cost-effectiveness analysis 
was developed to estimate the costs of complicated skin and soft tissues infec-
tions patients initiating therapy with ceftaroline, linezolid or vancomycin. Direct 
expenses associated with complicated skin and soft tissues infections and resulting 
follow-up costs were calculated using general tariff agreement of Russian obligatory 
insurance system and official national statistics. For reference, accepted exchange 
rate was 1 EUR = 40 RUB. Results: Compared to ceftaroline, linezolid or vanco-
mycin results in increases in drug therapy costs: 77 997 RUB (1 950 EUR) per patient 
in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient 
in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per 
patient in linezolid group (therapy duration – 12 days). The values of cost/clinical 
cure rate are estimated at 96 055 RUB (2 401 EUR) in ceftaroline group, 98 030 RUB (2 
451 EUR) in vancomycin group, and 138 860 RUB (3 472 EUR) in linezolid group per 
patient. ConClusions: The results of cost-effectiveness illustrate that ceftaroline 
is dominant in Russian patients with complicated skin and soft tissues infections 
who are initiating antimicrobials therapy compared with linezolid or vancomycin.
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objeCtives: Meticillin-resistant staphylococcus aureus (MRSA) is an important 
cause of antimicrobial-resistant health care-associated infections worldwide. Its 
prevalence remains high in the Greek hospital setting. Complicated skin and soft tis-
sue infections (cSSTIs) due to MRSA are associated with prolonged hospitalization, 
additional costs of care and significant morbidity. The purpose of this study was to 
conduct a cost-effectiveness analysis of different treatment scenarios in the man-
agement of MRSA-cSSTIs, under a third-party payer perspective. Methods: The 
model was based on a decision tree simulating costs and outcomes for a maximum of 
28 days, consisting of empiric, first-line and second-line treatment, for patients with 
MRSA-cSSTIs. Inpatient and outpatient health care services were included in the 
analysis. Data on efficacy of the pharmacotherapies under evaluation were derived 
from a recent meta-analysis (Bassetti et al 2013) and resource use was elicited via 
an expert panel. Economic results, expressed in Euros (2013), reflect the Greek social 
insurance setting. Results: Three different first→second line treatment scenarios 
(daptomycin→linezolid, linezolid→daptomycin, vancomycin→linezolid) were evalu-
ated, as recommended by the expert panel. Total management costs per patient 
were € 4,199, € 3,809, and € 3,900; quality adjusted life years (QALY) gained were 0.058, 
0.059 and 0.057 respectively for the above scenarios. The scenario containing first-
line linezolid proved to be a dominant therapeutic option vs. the other scenarios 
(less costly, higher QALYs), whereas first-line daptomycin scenario did not appear 
to be cost-effective vs. the respective vancomycin scenario (incremental cost-utility 
ratio € 243,932) in the management of MRSA-cSSTIs. Second line oral linezolid was 
used as continuation treatment after failure/intolerance or switch from intravenous 
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propofol in critically ill patients, and subsequently determining the best strategy 
for administering propofol. Methods: Costs of propofol-related infection and the 
different strategies of administration of propofol were computed according to the 
literature and microcosting method. The additional length of stay in ICU due to 
major infections related to propofol administration was estimated using the disabil-
ity model, assuming a cost of CHF 2’118/intensive care unit day (local cost). The cost 
of each strategy was estimated based on all costs and on the probability of major 
infections related to propofol administration. Results: According to the links 
found in the literature by genotyping bacteria (syringe-patient), we assumed that a 
patient has a mean 22.6% risk of developing an infection by a contaminated prepa-
ration of propofol. Thus, the ready-to-use syringe and syringes drawn from vials 
have an infection probability of 0.0014 [0.0009 – 0.0038] and 0.0118 [0.0056 – 0.0181] 
respectively. Probability of infection and the extended length of stay were the cost-
drivers of this analysis. Ready-to-use syringes of propofol saved money, decreasing 
the cost by at least CHF 251 per sedation. Ready-to-use syringes remained a cost 
saving strategy when the propofol related infection rate probability according to the 
literature was as high as 0.38%. ConClusions: Ready-to-use syringes of propofol 
save money by preventing major infections related to its administration.
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cost effectIVeNess of PrePex deVIce aNd dorsal–slIt techNIqUe for 
scalINg-UP adUlt safe MedIcal Male cIrcUMcIsIoN IN hIV PreVeNtIoN 
IN rUral ceNtral UgaNda
Kigenyi O., Kusiima J., Silas I.
Makerere University, Kampala, Uganda
objeCtives: Averting 20% of new HIV infections, the country has to achieve 80% 
national circumcision coverage. Given the inadequacy of human resource at cir-
cumcision centers in Uganda, we conducted a study to assess the cost-effectiveness 
of PrePex device (none surgical) and Dorsal-slit technique (surgical) for scaling-up 
adult safe medical male circumcision. Methods: In a four weeks cost effective-
ness course project during November 2012, we modeled the costs and effects of 
male circumcision of the 2 commonest strategies (Dorsal-slit technique as standard 
and PrePex device) used in Uganda. Effectiveness was defined as days of complete 
healing measured by costs from start of procedure to complete healing. This was 
the time until end of each procedure when all scores for drainage from incision, 
epithelialization, granulation of tissue, and edema were zero. We estimated costs 
and effects from previous studies in developing countries. Direct and indirect costs 
were included in a cost effectiveness analysis with limited government perspective. 
Costs for demand creation (training, patient counseling, and promotion campaigns) 
were excluded. One-way sensitivity analysis was done by varying costs and days of 
complete healing as main model parameters. Analyses were done using TreeAge 
Pro-2011 software. Results: PrePex (none surgical) utilized $52.13 over the days 
to complete healing (31 days) compared to dorsal-slit (surgical) utilizing $67.8 over 
the days to complete healing (23 days). PrePex was less costly ($52) and with lowest 
adverse-events (0.98) compared to dorsal-slit technique 0.96 adverse-events cost-
ing $65.9. PrePex device was mostly not sensitive to changes in costs and days to 
complete healing. ConClusions: PrePex device was cost-saving and cost effective.
PIN90
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theraPy IN tUrKey
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objeCtives: Two major clinical trials examined the efficacy of caspofungin (CAS) 
and voriconazole (VORI) for empiric therapy of febrile neutropaenia (FN). We inves-
tigated the cost-effectiveness of empiric CAS vs. VORI in FN from the Turkish per-
spective. Methods: The downstream consequences of CAS or VORI were captured 
through decision tree analysis. Outcome measures included success, breakthrough 
fungal infection, persistent base-line fungal infection, persistent fever, premature 
discontinuation and death. Probability data were extracted from the major stud-
ies. An expert panel estimated health care resource consumption and alternative 
treatment after initial failure with either agent. Cost was based on 2012 data using 
Turkish Lira (TL). Deterministic and probabilistic sensitivity analyses were per-
formed. Results: Compared to VORI, CAS was dominant by TL2,533, TL29,256 and 
TL2,536 per patient treated, successfully treated and patient survival, respectively 
(approx. USD1,414, 16,328 and 1,415). CAS had a higher likelihood of success and 
lower mortality than VOR (34.17% vs. 26.02% and 7.37% vs. 7.95%, respectively). 
Increasing the list cost or length of stay (LOS) for CAS by > 35% or 1.3 days, respec-
tively, changes the study outcomes. A decrease of list cost or LOS for VOR by > 32% 
or 1.2 days resulted in it being favorable. Removing fever resolution as part of the 
composite outcome afforded a contracted difference (CAS preferred by TL298 and 
299 per patient treated and surviving with VORI preferred by TL488 per patient 
successfully treated). Monte Carlo simulation of 10,000 subjects, with variability 
imputed on the outcome probabilities taken from the literature, LOS and hospitali-
sation costs, resulted in a 78.8% chance of favoring CAS. ConClusions: There is 
a high likelihood of CAS being cost-effective compared to VORI in the treatment of 
FN in Turkey. Sensitivity analyses highlighted a robust advantage towards CAS. The 
model is moderately sensitive to changes in LOS or cost of each agent.
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ecoNoMIc aNalysIs of Protease INhIBItors IN fIrst-lINe haart IN 
adUlt PatIeNts wIth hIV
Avxentyeva M.1, Goryaynov S.2, Rebrova O.3
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Assessment”, Moscow, Russia, 3Pirogov Russian National Research Medical University, Moscow, 
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using the constant discounting approach. The empirical , hyperbolic and propor-
tional discounting methods provided ICERs three times higher. The time-shifted and 
stepwise discounting led to favorable ICERs that were much below the NICE thresh-
old. ConClusions: The use of different discounting approaches had a considerable 
effect on the cost-effectiveness results. For preventive programs and vaccines con-
stant discounting approach was unfavorable since the health benefits are revealed 
decades later. Constant discounting could not justify the theory of social and indi-
vidual time preference. The empirical discounting though discounted the outcomes 
at a much slower rate in the long term; the approach remained unfavorable owing to 
the heavy discounting in the short term. The time-shifted and stepwise discounting 
were feasible for the vaccines as they related to the moment of risk reduction and 
were persistent with the time-preference theory, respectively.
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objeCtives: A pivotal clinical trial failed to demonstrate non-inferiority of voricona-
zole (VORI) vs. liposomal amphotericin B (LAMB) for empiric treatment of febrile neu-
tropaenia (FN). This study investigated the cost-effectiveness of the two options from 
the Turkish health care system’s perspective. Methods: A decision-tree analysis 
was used to capture downstream consequences of each agent. Outcome measures 
included success, breakthrough fungal infection, persistent base-line fungal infection, 
persistent fever, premature discontinuation and death. Probability data were extracted 
from the published clinical trial. Resource consumption and alternative treatment 
after initial failure with either agent were estimated by an expert panel. Cost was 
based on 2012 data within Turkey. Deterministic and probabilistic sensitivity analyses 
were performed to determine the model’s robustness. Results: Compared to LAMB, 
VORI was the cost-effective alternative per patient treated and per patient survival 
(by TL2,523 (approx USD1,396) and TL2,520 (approx USD1,394), respectively). LAMB 
was preferred when considering the cost per successfully treated patient (TL5,362 
difference in favor of LAMB, approx USD2,966). LAMB had a higher likelihood of suc-
cess (30.57% vs. 26.02%) and lower probability of death than VORI (5.92% vs. 7.95%). 
Increasing the list cost or length of stay (LOS) of VORI by > 32.4% or 1.2 days, respec-
tively, changes the study outcomes. Decreasing list cost or LOS for LAMB by > 15.8% 
or 1.0 days, respectively, resulted in LAMB becoming favorable. Monte Carlo simula-
tion (MCS) of 10,000 subjects, with variability imputed upon the published outcome 
probabilities, LOS and hospitalization costs, resulted in a 69.4% chance of favoring 
VORI. ConClusions: VORI appears to be cost-effective when compared to LAMB in 
the empiric treatment of FN from the Turkish perspective. One-way sensitivity analy-
ses did not change the conclusion with MCS indicating a 69.4% chance of favoring 
VORI. The outcome was highly sensitive to list cost and LOS.
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NoN-hoMogeNeoUs cost-effectIVeNess ModelINg of a New chg-
dressINg for PreVeNtINg catheter-related BloodstreaM INfectIoNs 
for PatIeNts IN INteNsIVe care UNIts
Maunoury F.1, Motrunich A.1, Ruckly S.2, Timsit J.F.2
1Statésia, Le Mans, France, 2Grenoble University Hospital, Grenoble, France
objeCtives: Catheter-related bloodstream infection (CRBSI) is a frequent (1-5/1000 
catheter-days) and life-threatening complication in intensive care unit (ICU), pre-
ventable by systematic use of a new antimicrobial transparent dressing containing 
a chlorhexidine gluconate (CHG) hydrogel (60% risk reduction in a recent RCT). Our 
purpose is to evaluate the advantages of routine use of the new CHG-dressing to 
secure central lines of patients in ICU from the medico-economic viewpoint compared 
to non-antimicrobial (reference). Both medical and economic criteria are embedded 
into an analytic decision model to support the choice of the best dressing strat-
egy. Methods: A 30-day ICU-time non-homogeneous markovian model comprises 
eight states: five combining either occurrence or no-occurrence of: CRBSI, contact 
dermatitis, and the need of a new central line; one for changing alternative dressing 
in case of dermatitis and two absorbent states (death and discharge). The probabili-
ties of events derive a multicentre RCT on 1,879 patients. Monte Carlo simulations 
of 1,000 patients are used for probabilistic sensitivity analysis and 95% confidence 
intervals (CI) calculations. The final health outcome is the number of CRBSI averted. 
Costs of ICU stay are updated from estimations of a French study from 2010. This 
economic evaluation takes into account ICU perspective in France. Results: The 
CHG-dressing prevents 11.75 infections (95% CI: [-19.64; -3.85], number needed to 
treat= 85) for 1,000 patients as estimated via probabilistic cost-effectiveness sensitivity 
analysis. The mean adjusted cost per patient is € 2013 21,391 [95% CI: € 20,339; € 22,443] 
for the CHG-dressing group and € 2013 20,882 [95% CI: € 19,905; € 21,859] for the reference 
dressing. ConClusions: The CHG-dressing, significantly more efficacious to prevent 
CRBSI when compared to the reference dressing, contributes to preserve patients’ 
health capital at the same cost for the ICU. According to the base case scenario the 
CHG-dressing is more cost-effective than the reference dressing.
PIN88
costs eValUatIoNs of ready-to-Use ProPofol syrINges VersUs 
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objeCtives: Primary nosocomial bloodstream infections (BSI) (5-15% of all infec-
tions) are associated with increased length of stay and additional hospital costs. 
Propofol infusions, commonly used for sedation in intensive care units (ICU), are 
formulated in lipid emulsion which promotes microbial growth. The present study 
aimed at identifying the probabilities and costs of contamination of syringes of 
